Mutual of America Capital Management LLC Has $8.83 Million Position in Zoetis Inc. (NYSE:ZTS)

Mutual of America Capital Management LLC lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 3.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 54,167 shares of the company’s stock after selling 1,746 shares during the period. Mutual of America Capital Management LLC’s holdings in Zoetis were worth $8,825,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Hancock Whitney Corp grew its stake in Zoetis by 0.3% during the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after acquiring an additional 61 shares in the last quarter. Strategy Asset Managers LLC boosted its holdings in shares of Zoetis by 3.5% during the third quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock worth $356,000 after purchasing an additional 62 shares during the period. VeraBank N.A. grew its position in Zoetis by 4.1% during the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock valued at $254,000 after purchasing an additional 62 shares in the last quarter. Procyon Advisors LLC increased its stake in Zoetis by 1.4% in the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock valued at $768,000 after buying an additional 63 shares during the period. Finally, Deseret Mutual Benefit Administrators lifted its position in Zoetis by 6.6% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock worth $170,000 after buying an additional 65 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders.

Zoetis Stock Up 1.6 %

Shares of Zoetis stock opened at $167.58 on Friday. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The stock has a 50 day moving average price of $166.30 and a two-hundred day moving average price of $177.30. The stock has a market capitalization of $75.04 billion, a P/E ratio of 30.64, a PEG ratio of 2.78 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.19%. Zoetis’s payout ratio is presently 36.56%.

Wall Street Analyst Weigh In

Several research firms have recently commented on ZTS. StockNews.com cut shares of Zoetis from a “buy” rating to a “hold” rating in a report on Tuesday, February 25th. Stifel Nicolaus lowered their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Piper Sandler raised their price target on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday. Barclays boosted their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Finally, UBS Group started coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. Two analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Zoetis has a consensus rating of “Buy” and a consensus target price of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.